Brain derived neurotropic factor in first-episode psychosis

Peter F Buckley, Anilkumar R Pillai, Denise Evans, Edna Stirewalt, Sahebarao Mahadik

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

There is much interest, derived from current neurochemical, genetic, and therapeutic research, in the role of brain neurotrophins in schizophrenia. Neurotrophins play key roles in neuronal development and differentiation (i.e., promoting dendritogenesis and synaptogenesis), and in orchestrating the neuronal response to stress/noxious stimuli. Additionally, neurotrophins are modulators across monominergic (dopamine and serotonin), gabaergic and cholinergic systems. These roles focus on important areas of the etiopathophysiology of schizophrenia. Clinical studies show reductions in brain-derived neurotrophic factor (BDNF) and nerve growth factor (NFG) in schizophrenic patients as compared to normal control subjects, as well as differences in patients receiving first-generation antipsychotics (FGAs) or second-generation antipsychotics (SGAs). We now report on BDNF levels in subjects with first-episode psychosis in comparison with normal healthy controls. Compared to normal controls (N = 14; 290.5 ± 38.81 pg/ml), first-episode psychotic patients showed significant reduction (N = 15; 135 ± 21.77 pg/ml; P = 0.001; f = 12.873) in plasma BDNF. Additionally, plasma BDNF levels showed a significant negative correlation (N = 13′ r = 0.584, P = 0.0362) only with positive symptom scores at base line and no significant correlations were found with any of the cognitive performance test battery or motor function test scores. Low BDNF levels at the onset of psychosis suggest that it may contribute to the pathogenesis of schizophrenia and/or perhaps could be a helpful neurobiological marker for possible early treatment intervention.

Original languageEnglish (US)
Pages (from-to)1-5
Number of pages5
JournalSchizophrenia Research
Volume91
Issue number1-3
DOIs
StatePublished - Mar 1 2007

Fingerprint

Brain-Derived Neurotrophic Factor
Psychotic Disorders
Nerve Growth Factors
Brain
Schizophrenia
Antipsychotic Agents
Therapeutic Human Experimentation
Genetic Research
Nerve Growth Factor
Cholinergic Agents
Dopamine
Serotonin

Keywords

  • Brain-derived neurotrophic factor
  • First-episode psychosis
  • Neurotrophins
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Brain derived neurotropic factor in first-episode psychosis. / Buckley, Peter F; Pillai, Anilkumar R; Evans, Denise; Stirewalt, Edna; Mahadik, Sahebarao.

In: Schizophrenia Research, Vol. 91, No. 1-3, 01.03.2007, p. 1-5.

Research output: Contribution to journalArticle

Buckley, Peter F ; Pillai, Anilkumar R ; Evans, Denise ; Stirewalt, Edna ; Mahadik, Sahebarao. / Brain derived neurotropic factor in first-episode psychosis. In: Schizophrenia Research. 2007 ; Vol. 91, No. 1-3. pp. 1-5.
@article{b9571279b7f2419db252d939a7c7f90c,
title = "Brain derived neurotropic factor in first-episode psychosis",
abstract = "There is much interest, derived from current neurochemical, genetic, and therapeutic research, in the role of brain neurotrophins in schizophrenia. Neurotrophins play key roles in neuronal development and differentiation (i.e., promoting dendritogenesis and synaptogenesis), and in orchestrating the neuronal response to stress/noxious stimuli. Additionally, neurotrophins are modulators across monominergic (dopamine and serotonin), gabaergic and cholinergic systems. These roles focus on important areas of the etiopathophysiology of schizophrenia. Clinical studies show reductions in brain-derived neurotrophic factor (BDNF) and nerve growth factor (NFG) in schizophrenic patients as compared to normal control subjects, as well as differences in patients receiving first-generation antipsychotics (FGAs) or second-generation antipsychotics (SGAs). We now report on BDNF levels in subjects with first-episode psychosis in comparison with normal healthy controls. Compared to normal controls (N = 14; 290.5 ± 38.81 pg/ml), first-episode psychotic patients showed significant reduction (N = 15; 135 ± 21.77 pg/ml; P = 0.001; f = 12.873) in plasma BDNF. Additionally, plasma BDNF levels showed a significant negative correlation (N = 13′ r = 0.584, P = 0.0362) only with positive symptom scores at base line and no significant correlations were found with any of the cognitive performance test battery or motor function test scores. Low BDNF levels at the onset of psychosis suggest that it may contribute to the pathogenesis of schizophrenia and/or perhaps could be a helpful neurobiological marker for possible early treatment intervention.",
keywords = "Brain-derived neurotrophic factor, First-episode psychosis, Neurotrophins, Schizophrenia",
author = "Buckley, {Peter F} and Pillai, {Anilkumar R} and Denise Evans and Edna Stirewalt and Sahebarao Mahadik",
year = "2007",
month = "3",
day = "1",
doi = "10.1016/j.schres.2006.12.026",
language = "English (US)",
volume = "91",
pages = "1--5",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Brain derived neurotropic factor in first-episode psychosis

AU - Buckley, Peter F

AU - Pillai, Anilkumar R

AU - Evans, Denise

AU - Stirewalt, Edna

AU - Mahadik, Sahebarao

PY - 2007/3/1

Y1 - 2007/3/1

N2 - There is much interest, derived from current neurochemical, genetic, and therapeutic research, in the role of brain neurotrophins in schizophrenia. Neurotrophins play key roles in neuronal development and differentiation (i.e., promoting dendritogenesis and synaptogenesis), and in orchestrating the neuronal response to stress/noxious stimuli. Additionally, neurotrophins are modulators across monominergic (dopamine and serotonin), gabaergic and cholinergic systems. These roles focus on important areas of the etiopathophysiology of schizophrenia. Clinical studies show reductions in brain-derived neurotrophic factor (BDNF) and nerve growth factor (NFG) in schizophrenic patients as compared to normal control subjects, as well as differences in patients receiving first-generation antipsychotics (FGAs) or second-generation antipsychotics (SGAs). We now report on BDNF levels in subjects with first-episode psychosis in comparison with normal healthy controls. Compared to normal controls (N = 14; 290.5 ± 38.81 pg/ml), first-episode psychotic patients showed significant reduction (N = 15; 135 ± 21.77 pg/ml; P = 0.001; f = 12.873) in plasma BDNF. Additionally, plasma BDNF levels showed a significant negative correlation (N = 13′ r = 0.584, P = 0.0362) only with positive symptom scores at base line and no significant correlations were found with any of the cognitive performance test battery or motor function test scores. Low BDNF levels at the onset of psychosis suggest that it may contribute to the pathogenesis of schizophrenia and/or perhaps could be a helpful neurobiological marker for possible early treatment intervention.

AB - There is much interest, derived from current neurochemical, genetic, and therapeutic research, in the role of brain neurotrophins in schizophrenia. Neurotrophins play key roles in neuronal development and differentiation (i.e., promoting dendritogenesis and synaptogenesis), and in orchestrating the neuronal response to stress/noxious stimuli. Additionally, neurotrophins are modulators across monominergic (dopamine and serotonin), gabaergic and cholinergic systems. These roles focus on important areas of the etiopathophysiology of schizophrenia. Clinical studies show reductions in brain-derived neurotrophic factor (BDNF) and nerve growth factor (NFG) in schizophrenic patients as compared to normal control subjects, as well as differences in patients receiving first-generation antipsychotics (FGAs) or second-generation antipsychotics (SGAs). We now report on BDNF levels in subjects with first-episode psychosis in comparison with normal healthy controls. Compared to normal controls (N = 14; 290.5 ± 38.81 pg/ml), first-episode psychotic patients showed significant reduction (N = 15; 135 ± 21.77 pg/ml; P = 0.001; f = 12.873) in plasma BDNF. Additionally, plasma BDNF levels showed a significant negative correlation (N = 13′ r = 0.584, P = 0.0362) only with positive symptom scores at base line and no significant correlations were found with any of the cognitive performance test battery or motor function test scores. Low BDNF levels at the onset of psychosis suggest that it may contribute to the pathogenesis of schizophrenia and/or perhaps could be a helpful neurobiological marker for possible early treatment intervention.

KW - Brain-derived neurotrophic factor

KW - First-episode psychosis

KW - Neurotrophins

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=33847254358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847254358&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2006.12.026

DO - 10.1016/j.schres.2006.12.026

M3 - Article

VL - 91

SP - 1

EP - 5

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -